Compare Eli Lilly And Co (LLY) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs NextEra Energy, Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while NextEra Energy, Inc. trades at $77.38 (market cap $161.39B). The key difference: Eli Lilly And Co is far larger — about 6.4× NextEra Energy, Inc.'s market cap, and NextEra Energy, Inc. pays the higher dividend (3.22%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and NextEra Energy, Inc. for 83 Days on average.
| LLY | NEE | |
|---|---|---|
Market Cap | $1.04T | $161.39B |
Volume | 3,064,878 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $1.28K | $97.88 |
52-Week Low | $799.57 | $75.49 |
Typical Hold Time | 93 Days | 83 Days |
Enterprise Value | $1.09T | $268.72B |
Dividend Yield | 0.59% | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
NextEra Energy (NEE) trades at $77.37, up 0.4% on the day, with a bearish technical signal but strong analyst support. Recent earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss. The company maintains robust profitability, with a net income margin of 32.4% and ROE of 17.23%. News highlights include participation in the Wolfe Research conference and a major $22.3 billion energy infrastructure project in Texas, signaling growth initiatives amid a challenging market.
Outlook is cautiously optimistic, with a consensus price target of $96.00 offering 24% upside. Risks include rising debt-to-asset ratios and macroeconomic pressures, but strong cash flow and strategic investments in clean energy provide long-term growth potential. Investors should weigh solid fundamentals against near-term technical weakness and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
